ISRAEL IN IP DISPUTE

The Jerusalem Post reports that Israeli Industry, Trade and Labor Minister Ehud Olmert will be meeting US trade representative Robert Zoellick today. At the same time, Ministry officials will be meeting with EU representatives. The subject of discussion is Israel’s upcoming new intellectual property legislation. The US and EU are calling for Israel to introduce data exclusivity, which protects the confidentiality of proprietary tests and clinical trial data used by a pharmaceutical firm while registering a drug. This protection prevents generic drug companies from using this data to develop the same drug for a specified period. The US provides a 5 year protection period, while the EU grants 10 years. However, Israel is proposing to only grant market exclusivity, which protects pharmaceutical products but not data.

The IPKat notes that while TRIPS Art.39(3) requires Member States to protect data disclosed in clinical or other trials, it does not specify the term of protection that is necessary.

More on data exclusivity here
The IPKat reveals more clinical secrets here, here and here
ISRAEL IN IP DISPUTE ISRAEL IN IP DISPUTE Reviewed by Anonymous on Monday, November 29, 2004 Rating: 5

3 comments:

  1. Think that could give you some Search Engine popularity, and traffic???

    ReplyDelete
  2. Learn how to quickly create an RSS feeds with our RSS feeder, for high link popularity and ultimately better search engine rankings.

    ReplyDelete
  3. a lot of premium products and services being offered for free. What’s best is that there is a seemingly

    ReplyDelete

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html

Powered by Blogger.